10

15

20

25

30



The Claims:

- 1. A process for providing a dosage form, wherein the process comprises the steps as follows:
- (a) blending an osmotic hydrogel and an osmotically effective solute to provide a composition that increases in volume in the presence of an aqueous fluid;
 - (b) blending a hydroxyalkylcellulose and water to provide a granulation solution;
- (c) spraying the granulation solution (b) onto the composition provided in (a) to provide granules;
- (d) blending a grug, a surfactant, and a member selected from the group consisting of a mono and diglyceride to provide a drug formulation;
 - (e) adding/the drug formulation (d) to a capsule;
 - (f) adding the sprayed composition of (c) to the capsule;
- (g) coating the capsule with a semipermeable composition to provide a membrane permeable to an agueous fluid; and
- (h) providing an exit in the membrane (g) for delivering the drug at a sustained-release and controlled rate over an extended time from the dosage form.
- √ 2. The process for providing the dosage form according to Claim 1, wherein step (b) precedes step (a).
- 73. The process for providing the dosage form according to Claim 1, wherein step (f) precedes step (e).
- *4. The process for providing the dosage form according to Claim 1, wherein the membrane (g) comprises a cellulose acetate and polyethylene glycol.
- The process for providing the dosage form according to Claim 1, wherein drug formulation comprises polyoxyl 35 castor oil and acetylated monoglyceride.
- † 6. The process for providing the dosage form according to Claim 1, wherein the drug (d) comprises a member selected from the group consisting

10

15

20


25

30



of a peptide, protein, protein anabolic hormone, growth promoting hormone, endocrine system hormone, porcine growth promoting hormone, bovine growth promoting hormone, equine growth promoting hormone, human growth promoting hormone, hormone derived from a pituitary gland, hormone derived from a hypothalmus gland, recombinant DNA, samatotropin, gonadotropic releasing hormone, follicle stimulating hormone, luteinizing hormone, LH-RH, insulin, colchicine, chlorionic gonadotropin, oxytocin, vasopressin, desmopressin, adrenocorticotropic hormone, prolactin, bypressin, thyroid stimulating hormone, secretin, pancreozymin, enkephalin and glucagon.

- The process for providing the dosage form according to Claim 1, wherein the membrane (g) comprises a thermoplastic polymer composition possessing a softening point of 40° C to 180° C.
- 7 8. The process for providing the dosage form according to Claim 1, wherein the drug formulation (d) comprises an emulsion drug formulation.
- The process for providing the dosage form according to Claim 1, χ9. wherein the drug formulation (d) comprises a two-phase emulsion and comprises an agent that imparts emulsification to the drug formulation comprising a member selected from the group consisting of polyoxyethylenated castor oil/comprising 9 moles to 52 moles of ethylene oxide, polyoxyethylenated sorbitan monopalmitate comprising 20 of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 20 mules of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 4 moles of ethylene oxide, polyoxyethylenated sorbitan tristearate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan trioleate comprising 20 moles of ethylene oxide, polyoxyethylenated stearic acid comprising 8 moles of ethylene oxide, polyoxyethylene lauryl ether, polyoxyethylenated stearic acid comptising 40 moles to 50 moles of ethylene oxide, polyoxyethylenated stearic acid comprising 50 moles of ethylene oxide, polyoxyethylenated stearyl alcohol comprising 2 moles of ethylene oxide, and polyoxyethylenated oleyl alcohol comprising 2 moles of ethylene oxide.



 11. The processs for providing the dosage form according to Claim
 1, wherein drug formulation self emulsifies.

1A GAA